Briz O, Macias R I R, Serrano M A, González-Gallego J, Bayón J E, Marin J J G
Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain.
Placenta. 2003 May;24(5):462-72. doi: 10.1053/plac.2002.0959.
Using plasma membrane vesicles from human trophoblast, carrier-mediated transport of unconjugated bilirubin (UCBR) has been reported. In the present work, using the in situ perfused rat placenta-maternal liver tandem, the relevance of this pathway in vivo was investigated. After single-pass perfusion of rat placenta through the umbilical artery with 0.25 micromol [(3)H]-UCBR, approximately 15 per cent of it was taken up by the placenta, detected in maternal serum (>96 per cent was unconjugated) and subsequently secreted into maternal bile (approximately 15 per cent of administered dose; >88 per cent was glucuronidated bilirubin). Co-administration through the umbilical artery of 0.25 micromol [(3)H]-UCBR and 2.5 micromol unlabelled UCBR, bromosulfophthalein, cholic acid or biliverdin IXalpha, reduced [(3)H]-UCBR placenta uptake, and the amount of radioactivity found in the maternal serum and bile. Co-administration into maternal jugular vein of 0.1 micromol [(3)H]-UCBR-a dose 3-fold higher than that reaching the maternal compartment in placenta perfusion experiments-and 1.0 micromol bromosulfophthalein, cholic acid or biliverdin IXalpha, resulted in no marked inhibition of the amount of radioactivity bile output. When antipyrine and [(3)H]-UCBR were continuously co-infused to the mother, similar antipyrine concentrations in maternal and foetal serum were reached in approximately 15 min, while progressive increase in [(3)H]-bilirubin concentrations in maternal serum above 70 microM was accompanied by a very low transfer of this compound into foetal compartment where [(3)H]-bilirubin concentrations were always <10 microM. These results suggest that the transfer of UCBR across the rat placenta occurs, without biotransformation, via a foetal-to-maternal mainly unidirectional pathway that can be cis-inhibited by UCBR and other cholephilic organic anions.
据报道,利用人滋养层细胞膜囊泡可实现未结合胆红素(UCBR)的载体介导转运。在本研究中,采用原位灌注大鼠胎盘-母体肝脏串联模型,研究了该途径在体内的相关性。通过脐动脉用0.25微摩尔[(3)H]-UCBR对大鼠胎盘进行单次灌注后,约15%被胎盘摄取,在母体血清中检测到(>96%为未结合型),随后分泌到母体胆汁中(约占给药剂量的15%;>88%为葡萄糖醛酸结合胆红素)。通过脐动脉共同给予0.25微摩尔[(3)H]-UCBR和2.5微摩尔未标记的UCBR、溴磺酚酞、胆酸或胆绿素IXα,可降低[(3)H]-UCBR的胎盘摄取量,以及母体血清和胆汁中的放射性活度。通过母体颈静脉共同给予0.1微摩尔[(3)H]-UCBR(该剂量比胎盘灌注实验中到达母体部分的剂量高3倍)和1.0微摩尔溴磺酚酞、胆酸或胆绿素IXα,并未显著抑制放射性胆汁输出量。当将安替比林和[(3)H]-UCBR持续共同输注给母体时,母体和胎儿血清中的安替比林浓度在约15分钟内达到相似水平,而母体血清中[(3)H]-胆红素浓度在70微摩尔以上逐渐升高时,该化合物向胎儿部分的转运非常低,胎儿部分[(3)H]-胆红素浓度始终<10微摩尔。这些结果表明,UCBR通过大鼠胎盘的转运发生,无需生物转化,通过主要从胎儿到母体的单向途径进行,该途径可被UCBR和其他亲胆有机阴离子顺式抑制。